DEP radiopharmaceutical data supports patent application
Filed with ASX · · 3 pages · English
Melbourne, Australia; 2 July 2026: Starpharma (ASX: SPL, US OTC: SPHRY), an innovative biotechnology company advancing dendrimer technology from the lab to the patient, today announces the filing of a new patent application supporting the use of its proprietary DEP® technology in radioligand therapy (RLT), following encouraging preclinical findings demonstrating a differentiated radiopharmaceutica
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- FDA confirms path to DEP HER2 first-in-human study
- Half Yearly Report and Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
- AGM Chair address and CEO presentation
- Upfront payment of USD $5.5 million received from Genentech
Later from Starpharma
- Positive DEP HER2-Lu preclinical data support Phase 1 entry
- DEP milestone triggers partner option fee
- Quarterly Activities Report and Appendix 4C
- Fully Underwritten Entitlement Offer to Raise $32 Million
- Entitlement Offer Investor Presentation
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma